Literature DB >> 26357794

Using Zero Balance Ultrafiltration with Dialysate as a Replacement Fluid for Hyperkalemia during Cardiopulmonary Bypass.

Michele Heath, Karthik Raghunathan, Ian Welsby, Cory Maxwell.   

Abstract

Avoiding or managing hyperkalemia during cardiac surgery, especially in a patient with chronic renal insufficiency, can be challenging. Hyperkalemic cardioplegia solution is usually administered to achieve and maintain an electrical arrest of the heart. This solution eventually mixes in with the systemic circulation, contributing to elevated systemic potassium levels. Administration of packed red blood cells, hemolysis, tissue damage, and acidosis are also common causes of hyperkalemia. Current strategies to avoid or manage hyperkalemia include minimizing the volume of cardioplegia administered, shifting potassium from the extracellular into the intracellular space (by the administration of sodium bicarbonate when the pH is low and/or dextrose-insulin when effects relatively independent of serum pH are desired), using zero-balanced ultrafiltration (Z-BUF) with normal saline as the replacement fluid (to remove potassium from the body rather than simply shift the electrolyte across cellular membranes), and, occasionally, hemodialysis (1). We report the application of Z-BUF using an electrolyte-balanced, low potassium dialysate solution rather than isotonic saline to avoid a high chloride load and the potential for hyperchloremic acidosis to successfully treat hyperkalemia while on cardiopulmonary bypass.

Entities:  

Mesh:

Year:  2014        PMID: 26357794      PMCID: PMC4566837     

Source DB:  PubMed          Journal:  J Extra Corpor Technol        ISSN: 0022-1058


  16 in total

1.  High-volume ultrafiltration with extracellular fluid replacement for the management of dialysis patients during cardiopulmonary bypass.

Authors:  Laurence W Lee; Steven Gabbott
Journal:  J Cardiothorac Vasc Anesth       Date:  2002-02       Impact factor: 2.628

Review 2.  Selection of dialysate and replacement fluids and management of electrolyte and Acid-base disturbances.

Authors:  Michael A Kraus
Journal:  Semin Dial       Date:  2009 Mar-Apr       Impact factor: 3.455

3.  Lest we forget: heparin-induced hyperkalemia.

Authors:  Balu Bhaskar; John F Fraser; Dan Mullaney
Journal:  J Cardiothorac Vasc Anesth       Date:  2011-01-19       Impact factor: 2.628

4.  A randomized, double-blind comparison of lactated Ringer's solution and 0.9% NaCl during renal transplantation.

Authors:  Catherine M N O'Malley; Robert J Frumento; Mark A Hardy; Alan I Benvenisty; Tricia E Brentjens; John S Mercer; Elliott Bennett-Guerrero
Journal:  Anesth Analg       Date:  2005-05       Impact factor: 5.108

5.  Washing of irradiated red blood cells prevents hyperkalaemia during cardiopulmonary bypass in neonates and infants undergoing surgery for complex congenital heart disease.

Authors:  Christine G Swindell; Thomas A Barker; Simon P McGuirk; Timothy J Jones; David J Barron; William J Brawn; Angela Horsburgh; Robert G Willetts
Journal:  Eur J Cardiothorac Surg       Date:  2007-02-08       Impact factor: 4.191

6.  High-volume, zero-balanced hemofiltration to reduce delayed inflammatory response to cardiopulmonary bypass in children.

Authors:  D Journois; D Israel-Biet; P Pouard; B Rolland; W Silvester; P Vouhé; D Safran
Journal:  Anesthesiology       Date:  1996-11       Impact factor: 7.892

7.  Changing the priming solution from Ringer's to Hartmann's solution is associated with less metabolic acidosis during cardiopulmonary bypass.

Authors:  R P Alston; C Theodosiou; K Sanger
Journal:  Perfusion       Date:  2007-11       Impact factor: 1.972

Review 8.  Continuous renal replacement therapies: an update.

Authors:  M Manns; M H Sigler; B P Teehan
Journal:  Am J Kidney Dis       Date:  1998-08       Impact factor: 8.860

9.  Metabolic acidosis developing during cardiopulmonary bypass is related to a decrease in strong ion difference.

Authors:  R Peter Alston; Laura Cormack; Catherine Collinson
Journal:  Perfusion       Date:  2004-05       Impact factor: 1.972

Review 10.  A balanced view of balanced solutions.

Authors:  Bertrand Guidet; Neil Soni; Giorgio Della Rocca; Sibylle Kozek; Benoît Vallet; Djillali Annane; Mike James
Journal:  Crit Care       Date:  2010-10-21       Impact factor: 9.097

View more
  6 in total

1.  Cold Agglutinin Autoantibodies in a Patient without a Visible Coronary Sinus Ostium: Strategies for Myocardial Protection without Using Retrograde Cardioplegia.

Authors:  Michele Heath; Suraj Yalamuri; Julie Walker; Cory Maxwell; Adam Williams; Sharon McCartney; Mani Daneshmand
Journal:  J Extra Corpor Technol       Date:  2016-06

2.  Zero-Balance Ultrafiltration during Cardiopulmonary Bypass Is Associated with Decreased Urine Output.

Authors:  Alfred H Stammers; Eric A Tesdahl; Linda B Mongero; Kirti P Patel; Courtney C Petersen; Jennifer Arriola Vucovich; Jeffrey P Jacobs
Journal:  J Extra Corpor Technol       Date:  2021-03

3.  Kidney Replacement Therapy for Patients Requiring Cardiopulmonary Bypass Support during Cardiac Surgery.

Authors:  Jacob S Stevens; Jai Radhakrishnan
Journal:  Clin J Am Soc Nephrol       Date:  2021-10-27       Impact factor: 8.237

Review 4.  American Society of ExtraCorporeal Technology: Development of Standards and Guidelines for Pediatric and Congenital Perfusion Practice (2019).

Authors:  Molly E Oldeen; Ronald E Angona; Ashley Hodge; Tom Klein
Journal:  J Extra Corpor Technol       Date:  2020-12

5.  Antithrombotic properties of hemofilter coated with polymer having a hydrophilic blood-contacting layer.

Authors:  Masashi Tagaya; Kazunobu Hara; Shunsuke Takahashi; Saki Nagoshi; Hiroki Handa; Shinya Okano; Takuo Murataka
Journal:  Int J Artif Organs       Date:  2018-11-29       Impact factor: 1.595

6.  Zero balance ultrafiltration using dialysate during nationwide bicarbonate shortage: a retrospective analysis.

Authors:  Ryan Mullane; Lance Fristoe; Nicholas W Markin; Tara R Brakke; Helen Mari Merritt-Genore; Aleem Siddique; Clifford D Miles; Troy J Plumb
Journal:  J Cardiothorac Surg       Date:  2019-09-10       Impact factor: 1.637

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.